Lung Cancer Diagnostics Market Size Analysis and Top Companies
The global lung cancer diagnostics market size is projected to hit around USD 8.87 billion by 2034 from USD 4.71 billion in 2024 with a CAGR of 6.53%. The top companies operating in the lung cancer diagnostics are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Illumina Inc, Agilent Technologies, Qiagen, Abbott, Bio-Rad, Neogenomics Laboratories, bioMérieux, Myriad Genetics, Inc, and Others.
Market Report Coverage
| Report Coverage |
Details |
| Market Size by 2033 |
USD 8.87 Billion |
| Market Size in 2023 |
USD 4.71 Billion |
| Market Growth Rate from 2023 to 2033 |
CAGR of 6.53% |
| Largest Market |
North America |
| Base Year |
2023 |
| Forecast Period |
2023 to 2033 |
| Segments Covered |
Type, Test, End Use, and Regions |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America and Middle East, & Africa |
Lung Cancer Diagnostics Key Players
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific
- Illumina Inc
- Agilent Technologies
- Qiagen
- Abbott
- Bio-Rad
- Neogenomics Laboratories
- bioMérieux
- Myriad Genetics, Inc
Latest Announcements by Industry Leaders
- In July 2024, the CEO of Roche Diagnostics commented that, access to diagnostic testing is critical for the delivery of healthcare globally and we are confident that the LumiraDx platform and technology will help us in case the availability of testing, especially in settings such as primary care and low and middle-income countries.
Recent Developments
- In March 2023, Agilent Technologies Inc. acquired Resolution Bioscience Inc. to expand the NGS-based cancer treatment capabilities. This acquisition further boosts Agilent's position in the cancer diagnostics market.
- In March 2023, Roche declared approval from the U.S. FDA for VENTANA PD-L1 (SP263) Assay. SP263 helps in advising immunotherapy non-small cell lung cancer (NSCLC) patients.
- In October 2022, Quest Diagnostics embarked on a renewed collaboration with Decode Health, marking a new phase in their partnership.
- In August 2022, F. Hoffmann-La Roche Ltd. launched the Digital LightCycler System, a cutting-edge digital PCR system aiding clinical researchers in comprehending cancer, genetic diseases, and infections.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
